Shire To Strengthen CNS Focus With Option On Heptares' Novel Parkinson's Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire Pharmaceuticals takes an option on Heptares' efforts to develop novel adenosine antagonists for Parkinson's disease.
You may also be interested in...
Shire Exercises Option On Heptares' Preclinical Candidate In $190 Million Deal
The U.K.'s G-protein coupled receptor specialist, Heptares, could receive up to $190 million plus royalties from Shire as it concludes its first product out-licensing agreement.
Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
The last five years have seen an explosion in novel approaches to Parkinson’s disease.
Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
The last five years have seen an explosion in novel approaches to Parkinson’s disease.